ReviewFrontiers in immunology2026
Ferroptosis-mediated metabolic reprogramming as a driver of the inflammatory microenvironment in neutrophilic asthma: a perspective.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutrophilic asthma is a severe asthma subtype marked by persistent airway neutrophilia, Th17-skewed inflammation, and poor responsiveness to glucocorticoids. The mechanisms driving chronic neutrophilic inflammation and corticosteroid resistance remain incompletely understood. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and redox imbalance. Emerging evidence suggests that ferroptosis is closely linked to cellular metabolism and immune regulation in inflammatory diseases. In this perspective article, we propose a hypothesis-generating framework in which ferroptosis-associated metabolic dysregulation may contribute to the development and persistence of neutrophilic asthma. Specifically, increased acyl-CoA synthetase long-chain family member 4 (ACSL4)-mediated phospholipid remodeling, enhanced fatty acid oxidation, nicotinamide adenine dinucleotide phosphate (NADPH) depletion, glutathione exhaustion, impaired glutathione peroxidase 4 (GPX4) function, and lipid peroxide amplification may collectively heighten neutrophil susceptibility to ferroptosis. We further propose a self-amplifying "ferroptotic relay," whereby ferroptotic neutrophils release oxidized lipid mediators and damage-associated molecular patterns (DAMPs) that drive inflammatory amplification, adaptive immune modulation, and sustained neutrophil recruitment within the airway microenvironment. We also examine how this ferroptosis-metabolism axis may contribute to chronic airway inflammation, glucocorticoid resistance, and disease heterogeneity. Finally, we highlight potential therapeutic opportunities involving ferroptosis-targeting agents, metabolic interventions, and biomarker-guided patient stratification. Although direct evidence for neutrophil ferroptosis in human neutrophilic asthma is still lacking, this framework may offer a conceptual foundation for future mechanistic, translational, and clinical investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.